218 related articles for article (PubMed ID: 17933531)
1. Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.
Luci DK; Ghosh S; Smith CE; Qi J; Wang Y; Haertlein B; Parry TJ; Li J; Almond HR; Minor LK; Damiano BP; Kinney WA; Maryanoff BE; Lawson EC
Bioorg Med Chem Lett; 2007 Dec; 17(23):6489-92. PubMed ID: 17933531
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
Chatenet D; Dubessy C; Boularan C; Scalbert E; Pfeiffer B; Renard P; Lihrmann I; Pacaud P; Tonon MC; Vaudry H; Leprince J
J Med Chem; 2006 Nov; 49(24):7234-8. PubMed ID: 17125276
[TBL] [Abstract][Full Text] [Related]
3. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.
Lawson EC; Luci DK; Ghosh S; Kinney WA; Reynolds CH; Qi J; Smith CE; Wang Y; Minor LK; Haertlein BJ; Parry TJ; Damiano BP; Maryanoff BE
J Med Chem; 2009 Dec; 52(23):7432-45. PubMed ID: 19731961
[TBL] [Abstract][Full Text] [Related]
5. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
[TBL] [Abstract][Full Text] [Related]
6. 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.
Jin J; Wang Y; Wang F; Shi D; Erhard KF; Wu Z; Guida BF; Lawrence SK; Behm DJ; Disa J; Vaidya KS; Evans C; McMillan LJ; Rivero RA; Neeb MJ; Douglas SA
Bioorg Med Chem Lett; 2008 May; 18(9):2860-4. PubMed ID: 18420409
[TBL] [Abstract][Full Text] [Related]
7. 5-HT2C receptor agonists with potential anorectic activity.
Yoon G; Jeong HJ; Kim JJ; Cheon SH
Arch Pharm Res; 2008 Aug; 31(8):989-94. PubMed ID: 18787786
[TBL] [Abstract][Full Text] [Related]
8. [A vasoactive peptide: urotensin II].
Liu GQ; Zeng ZP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):525-8. PubMed ID: 16178453
[TBL] [Abstract][Full Text] [Related]
9. Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats.
Gendron G; Simard B; Gobeil F; Sirois P; D'Orléans-Juste P; Regoli D
Can J Physiol Pharmacol; 2004 Jan; 82(1):16-21. PubMed ID: 15052301
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.
Tandon R; Soni A; Singh RK; Sodhi R; Seth MK; Sinha S; Sahdev S; Dhage G; Das B; Dastidar SG; Shriumalla RK; Yonesu K; Marumoto S; Nagayama T
Eur J Pharmacol; 2020 Nov; 886():173391. PubMed ID: 32745605
[TBL] [Abstract][Full Text] [Related]
11. A new ligand for the urotensin II receptor.
Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.
Lescot E; Bureau R; Rault S
Peptides; 2008 May; 29(5):680-90. PubMed ID: 18022732
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Sams AG; Hentzer M; Mikkelsen GK; Larsen K; Bundgaard C; Plath N; Christoffersen CT; Bang-Andersen B
J Med Chem; 2010 Sep; 53(17):6386-97. PubMed ID: 20684563
[TBL] [Abstract][Full Text] [Related]
15. Ligand-supported purification of the urotensin-II receptor.
Du AT; Onan D; Dinh DT; Lew MJ; Ziogas J; Aguilar MI; Pattenden LK; Thomas WG
Mol Pharmacol; 2010 Oct; 78(4):639-47. PubMed ID: 20647393
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study on human urotensin II.
Guerrini R; Camarda V; Marzola E; Arduin M; Calo G; Spagnol M; Rizzi A; Salvadori S; Regoli D
J Pept Sci; 2005 Feb; 11(2):85-90. PubMed ID: 15635628
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11).
Marzola E; Camarda V; Batuwangala M; Lambert DG; Calo' G; Guerrini R; Trapella C; Regoli D; Tomatis R; Salvadori S
Peptides; 2008 May; 29(5):674-9. PubMed ID: 17822806
[TBL] [Abstract][Full Text] [Related]
19. Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction.
Dubessy C; Cartier D; Lectez B; Bucharles C; Chartrel N; Montero-Hadjadje M; Bizet P; Chatenet D; Tostivint H; Scalbert E; Leprince J; Vaudry H; Jégou S; Lihrmann I
J Neurochem; 2008 Oct; 107(2):361-74. PubMed ID: 18710417
[TBL] [Abstract][Full Text] [Related]
20. Urotensin II: the old kid in town.
Onan D; Hannan RD; Thomas WG
Trends Endocrinol Metab; 2004; 15(4):175-82. PubMed ID: 15109617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
